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ABSTRACT
Little is known about how CD4 and viral load testing have evolved following
implementation of universal test and treat (UTT) in African settings. We
reviewed World Health Organization (WHO) guidance from 2013 to 2018,
and compared it against national HIV policies in Malawi, Tanzania and
South Africa. Three surveys rounds were conducted in 2013, 2016 and
2017–2018 in 33 health facilities across the three settings to assess
implementation of national policies on the use of biological markers.
Qualitative interviews were conducted with 26 HIV policymakers or
programme managers, 21 providers and 66 people living with HIV to
explore understandings and experiences of these tests. Various factors
influenced adoption and implementation of WHO guidance, including
historical policies on CD4 counts, governance issues, supply chain
challenges and funding mechanisms. Facility-level practices relating to the
use of these tests often diverged from national policies. Patients and
providers valued both tests, but did not always understand their roles. In
addition to continued support for scaling-up viral load testing, renewed
focus should be placed on the ongoing value of point-of-care CD4 tests in
the UTT era, including its role in assessing disease progression and
informing clinical management of cases to reduce HIV-related mortality.
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Introduction
The past two decades have seen a rapid expansion in coverage with HIV treatment services for
people living with HIV in sub-Saharan Africa, facilitated by national and international initiatives
and resources (UNAIDS, 2014). Until recently, in most sub-Saharan African countries, CD4 cell
counts represented the mainstay for assessing the immunological status of HIV patients, guiding
decisions about eligibility for initiating HIV treatment, and for transitioning patients with poor
immunological response to first-line treatment antiretroviral therapy (ART) regimens onto
second-line drugs (World Health Organisation, 2010). In 2015, the World Health Organization
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(WHO) recommended that patients diagnosed with HIV should initiate ART at any CD4 cell count
(World Health Organisation, 2015), a strategy known as ‘universal test and treat’ (UTT). The wide-
spread adoption of UTT in sub-Saharan Africa has been recognised as a critical step in moving
towards targets to eliminate AIDS by 2030 (Nsanzimana et al., 2015; United States Agency Intena-
tional Development, 2014).
While CD4 cell counts (hereafter referred to as CD4) provide an indication of the strength of the
immune system, it does not report viral activity, which is best measured through a viral load test.
However, compared with CD4 testing, viral load testing is expensive and more technically complex,
reasons which were widely cited as inhibiting its wide-scale use in most sub-Saharan countries
during the first decade of ART scale up. As evidence on the benefits of viral load monitoring to pre-
serve the lifespan of first-line regimens and improve patient outcomes has become established, the
WHO recommended viral load (VL) monitoring as part of routine care for monitoring adherence
and treatment failure among people taking ART in all settings (World Health Organization, 2017;
World Health Organization, 2016).
Frontline access to CD4 remains essential for assessing disease progression (World Health Organiz-
ation, 2017), identifying people diagnosed late with HIV (as indicated by a CD4 < 350 cells/μL) (Fomun-
dam et al., 2017), informing differentiated care models (World Health Organization, 2017) and, more
broadly, providing healthcare workers with an objective measure of a patients’ health (Ford et al., 2017).
However, there are several factors that have undermined their use including the growing availability of
VL testing and recent guidance on its use, adoption of UTT, and a decrease in donor support for CD4
testing (Medecins sans Frontières, 2017; PEPFAR, 2019). As a result, several sub-Saharan African
countries have drastically reduced CD4 monitoring in favour of increased VL testing (United States
Agency Intenational Development, 2016), and CD4 tests performed in some low- or middle-income
countries are not been optimally utilised to inform clinical management (Haas et al., 2015). These con-
cerns are exacerbated by suggestions that coverage of VL monitoring remains limited in sub-Saharan
Africa settings (Ford et al., 2014), and even where the scale-up of VL testing is underway, the test results
are used sub-optimally for informing clinical decisions (Ehrenkranz et al., 2019).
Recognising the ongoing value of conducting both VL and CD4 testing, we investigated the extent
to which national policies on the use of each biological marker reflect WHO guidance, and the degree
to which national directives on their use are implemented at the facility level in rural Tanzania,
Malawi and South Africa. We also explore the challenges to their implementation from the perspec-
tives of in-country stakeholders, and experiences with their use among patients and providers.
Methods
This study draws on data from the ‘Strengthening health systems for the application of universal test
and treat’ (SHAPE UTT) study. The SHAPE UTT study is a multi-country health systems research
project investigating the policy implementation and health systems impacts of HIV test and treat
policies in these three countries. This study uses survey data from heath facilities serving the popu-
lations of three health and demographic surveillance sites in Tanzania (Ifakara), Malawi (Karonga)
and South Africa (uMkhanyakude) to assess the extent to which national policies on VL and CD4
testing are implemented in practice. We also draw on data from key informant interviews to contex-
tualise the policy content and national implementation strategies, and from qualitative interviews
with service providers and service users to explore how tests are experienced and understood in
everyday clinical practice (see Table 1 for study site and participant characteristics).
Policy review
A review of national HIV policies from 2013 to 2017 was conducted to describe adoption of policies
regarding CD4 and VL measures within each of the three countries (Table 2). WHO guidance was
also reviewed for the same time period and compared against national policies. The methods for the
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policy review have been described elsewhere (Ambia et al., 2017; Church et al., 2015; Jones et al.,
2019), but in brief, involved a consultation with HIV researchers and practitioners, and a review
of the published literature to define key policy indicators related to the delivery of HIV care and
treatment services. For the purposes of this analysis, details of policies directing the implementation
of CD4 and VL testing were extracted into an Excel spreadsheet which captured the key policy con-
tent, policy document name and publication date for comparison across countries.
Facility survey
Three rounds of health facility surveys were conducted in 2015, 2016 and 2017/2018 in health facili-
ties in Karonga, Malawi (n=5), Ifakara, Tanzania (n=11) and uMkhanyakude, South Africa (n=17).
The development and details of the questionnaire have been described previously (Church et al.,
2017). The questionnaire was administered in English with the staffmember in charge of each facility
and covered all components of HIV service delivery. For this analysis, responses to two questions
relating to implementation of CD4 testing, and six to VL testing, were extracted from the database.
Descriptive statistics were used to report the implementation of CD4 and VL testing by site.
Qualitative data collection
Key informant interviews
Between April and June 2019, we conducted 26 key informant (KI) interviews with policy makers,
donors and programme managers including regional/provincial implementing partners in Malawi
(n=10), Tanzania (n=11) and South Africa (n=5). The overarching aim of the in-depth interviews
was to explore how policy processes, context and various actors influenced the adoption and
implementation of UTT and the subsequent impacts on the health system. Questions were asked
to understand influences on policy development and adoption processes in each country and the
timeline for Option B+ and UTT formulation, adoption and implementation. We explored factors
that were perceived to have facilitated or inhibited the adoption and implementation of UTT, with
specific probes pertaining to relevant health systems components, including the workforce (training,
Table 1. HDSS information, facility survey details and qualitative interview participants.
South Africa Malawi Tanzania
HDSS information HDSS site name uMkhanyakude Karonga Ifakara
Size of HDSS site (km2) 438 135 2400
Population of HDSS site 90,000 42,555 170,000
HIV prevalence in the HDSS 35.20% 9.60% 7%
Facility survey Dates
Round 1 Jan-15 Dec-13 Nov 2013–March
2014
Round 2 May–June 2016 May-15 Sept–Oct 2015
Round 3 Dec 2017–Jan
2018
Nov–Dec
2017
Nov–Dec 2017
No. of facilities 17** 6* 12
Type of facility
Small clinic/ dispensary 16 1 3
Large clinic/ small health centre 1 2 0
Large health centre/ sub-district hospital 0 3 6
District/ referral hospital 0 0 3
Qualitative
interivews
Key informant Interviews 5 10 11
Health care workers 7 6 7
Service Users
HIV+ Pregnant & Post-partum women 8 5 8
HIV+ women who have transitioned into to
routine HIV care
6 7 4
HIV+ women who are currently not engaged
in care
5 6 2
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cadre, numbers) service delivery (coverage, access, quality), access to essential medicines and technol-
ogies (including CD4 and VL testing), health information systems and health systems financing. The
interviews were conducted in English by experienced local researchers in Malawi and Tanzania and
by the senior study investigator in South Africa, and were digitally recorded.
In-depth interviews with health workers and people living with HIV
In-depth interviews (IDIs) were conducted with women receiving prevention of mother-to-child
transmission (PMTCT) services during their antenatal care (ANC) and post-pregnancy, and health
workers providing these services (Table 1). In each of the sites, health facilities were stratified by type
Table 2. Policy documents reviewed by country and year.
Country # Author Name year
1 The Ministry of Health The Clinical Management of HIV in Adults and Children 2011
Malawi 2 The Ministry of Health Consolidated Guidelines for the Use of ART for Treating
and Preventing HIV Infection.
2013
3 The Ministry of Health Consolidated Strategic Information Guidelines. 2015
4 The Ministry of Health Consolidated Guidelines on HIV Testing Services. 2015
5 The Ministry of Health National Strategic plan for HIV and AIDS (2015–2020). 2015
6 The Ministry of Health Consolidated Guidelines for the Prevention, Diagnosis,
Treatment and Care for Key Populations.
2016
7 The Ministry of Health Guidelines on HIV Self-Testing and Partner Notification. 2016
8 The Ministry of Health National Health Information System Policy. 2016
9 The Ministry of Health Consolidated Guidelines for the Use of ART for Treating
and Preventing HIV Infection.
2016
10 The Ministry of Health Guidelines for the Clinical Management of HIV, 3rd
Edition.
2016
11 The Ministry of Health HIV testing Services Guidelines. 2016
12 The Ministry of Health Guidelines on Patient-Centred HIV patient monitoring
and case surveillance.
2017
The United
Republic of
Tanzania
1 Ministry of Health and Social
Welfare
National Guidelines for Comprehensive Care Services for
Prevention of Mother-to-Child Transmission of HIV
and Keeping Mothers Alive,
2013
2 The Prime Ministers Office Third National Multi-sectoral Strategic Framework for
HIV and AIDS,
2013
3 Ministry of Health, Community
Development, Gender, Elderly and
Children
Antenatal Care Guidelines, 2014
4 National AIDS Control Programme. National Guidelines For the Management of HIV and
AIDS. Dar es Salaam.
2015
5 Ministry of Health and Social
Welfare
Health Sector Strategic Plan 2015–2020 (HSSP IV):
Reaching all Households with Quality Health Care,
2015
6 Ministry of Health and Social
Welfare
National Operational Plan for Scaling up HIV Viral
Load testing
2015
7 Ministry of Health, Community
Development, Gender, Elderly and
Children
The National Guidelines for the Management of HIV and
AIDS, (Sixth Edition).
2017
South Africa 1 National Department of Health The South African Antiretroviral Treatment Guidelines. 2013
2 National Department of Health Guidelines for Maternity Care in South Africa, A Manual
for Clinics, Community Health Centres and District
Hospitals.
2015
3 National Department of Health South African Prevention of Mother to Child Guidelines. 2015
4 National Department of Health National HIV Counselling and Testing Policy Guidelines. 2015
5 National Department of Health National Consolidated Guidelines for the Prevention of
Mother to Child transmission of HIV (PMTCT) and the
Management of HIV in Children, Adolescents and
Adults.
2015
6 National Department of Health National HIV Testing Services Policy. 2016
7 National Department of Health South Africa’s National Strategic Plan for HIV, TB and
STIs. 2017–2022
2017
8 National Department of Health White Paper National Health Insurance for South Africa.
Towards Universal Health Coverage.
2017
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Table 3. Selected Policy guidance relating to CD4 and Viral load testing.
2013 2015 2017
Use of CD4 counts South
Africa
• Pre ART screening to assess ART eligibility
• Annual monitoring after ART initiation for adults.
• Same as 2013 • Same as 2013/5
• to determine the need for OI
prophylaxis
• CD4 tests every six months, baseline
>200 cells/μL or greater on ART,
• routine CD4+ testing stopped once VL
is suppressed and remains suppressed.
Malawi • Pre ART screening to assess ART eligibility,
• no routine scheduled CD4 monitoring
Same as 2013 • Same as 2013/5
• targeted CD4 tests by specialists for
complicated cases
Tanzania • Pre ART screening to assess ART eligibility,
• routine monitoring at 6 months
• Same as 2013,
• if IRIS or treatment failure is suspected then more
frequent testing advised
• Same as 2013/15
• additionally, if VL not available should
be done at baseline and then every 6
months,
Where CD4 tests can be
conducted
South
Africa
Unclear in policy documents Unclear in policy documents Unclear in policy documents
Malawi District hospitals and high volume sites All sites Point of care: ‘ to prioritise patients for
urgent linkage to care and ART
initiation’
Tanzania Not specified Zonal and regional hospitals No-longer specified
Recommended
turnaround time for CD4
tests
South
Africa
Not mentioned 1 week for pregnant women Not clear
Malawi Next appointment date so can be up to 3 months CD4 counts no-longer supported CD4 counts no-longer supported
Tanzania Not specified 3–7 days for PMTCT Not clear
Adherence sessions pre
ART
South
Africa
Not specified Not specified Yes – every visit
Malawi Two Two Two
Tanzania Three Three Three
Use of Viral load testing South
Africa
• After ART initiation to assess treatment failure
• routine at 6months and then annually
• Same as 2013 • Same as 2013/15
• to assess drug toxicity
Malawi • After ART initiation to assess treatment failure
• at 6 months after ART initiation, then 2 years then
bi-annual.
• if treatment failure suspected before starting 2nd
line
• Same as 2013 –
• collect catch-up VL sample at the next opportunity if
the regular schedule was missed
• To assess adherence to 2nd line treatment
No change
Tanzania Not specified To assess adherence prior to concluding treatment
failure, conducted after 6 months unless >1000
copies, then done at 3 months
Same as 2015 plus Viral load every 6
months
(Continued )
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Table 3. Continued.
2013 2015 2017
Other lab tests required
pre ART initiation
South
Africa
HB, FBC, Creatinine if TDF, ALT if NVP. Same as 2013 plus fasting cholesterol and TG Same as 2015
Malawi Confirmatory HIV test to rule out mix up of test
results – no other lab tests required at baseline
before starting ART.
No change No change
Tanzania HB, FBC, Creatine if TDF, ALT for NVP, Same as 2013, plus rapid test for syphilis and Hepatitis B
and C serology.,
Same as 2013
Other lab tests required
post ART initiation
South
Africa
• ALT if on NVP & rash or symptoms of Hepatitis,
• FBC at month 3 and 6 if on AZT,
• Creatinine at month 3 and 6, 1 year then annual if
on TDF,
• Fasting cholesterol and triglycerides at month 3 if
on LPV/
• Same as 2013
• SCR and eGRF at 3,6,12 and then annually if on TDF
Same as 2015
Malawi Lab tests focused on CD4 and VL Same as 2013 Same as 2013
Tanzania • ALT if on NVP and has rashes of symptoms of
hepatitis,
• FBC every 6 months,
• annual Creatinine,
• ALT If on AZT/3TC/NVP or 2nd line 6 monthly,
• FBC, If on AZT week 4 and 6 monthly thereafter,
• Creatinine If on TDF every 6 months, if on 2nd line bsln
then annually,
• Fasting cholesterol and triglycerides if on 2nd line bsln,
6 months and then every 12 months.
• Same as 2015 plus Viral load every 6
months,
• urine analysis for TB,
• pregnancy tests,
• liver and renal function
• hepatitis B,
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(hospital verses smaller facility) and location (district centre verses remote). One hospital, one
remote and one district centre facility were then randomly selected.
IDIs were conducted by trained fieldworkers in the local vernacular and lasted approximately 45–
90 min. We chose to use IDIs over focus group discussions in order to avoid significant disruptions
in service provision, and because the common power dynamics between different cadre of health
workers may have led to a few dominant voices giving more opinions, or lower cadre staff feeling
unwilling to express themselves in front of their superiors, particularly to dissent. IDIs were con-
ducted in a private location and were audio-recorded with permission. Among health workers, topics
included provision of HIV services and changes since the introduction of UTT, familiarity with
guidelines and how they were implemented, and perceived health systems impacts of implementing
UTT policies. Probes focused on the same health systems components which guided the KI inter-
views. Amongst service users, topics covered a woman’s experiences of their first ANC visit and
HIV testing process. For women living with HIV, experiences of treatment initiation, longer term
care provision (including their experiences with and understanding of CD4 and VL tests) and,
where appropriate, reasons for care disengagement were also explored. Interviews began by asking
women living with HIV how they perceived their health to be, and how they knew how their body
was responding to ART. Probes were then used to explore more specifically what they knew about
CD4 and VL tests, where they had garnered this information, their understanding of why they were
used and what the results meant, and their experiences of ever having their VL and CD4 tested. Deb-
riefings were held after each interview between field workers and the study coordinator, with weekly
joint teleconferences between the lead researchers to discuss similarities and differences in the emer-
ging findings across the three sites. Interview summaries were written in English by interviewers and
shared with other researchers to guide the weekly discussions.
Qualitative data analysis
Interviews were transcribed and those with service providers and users were translated into English.
Data were coded with the aid of Nvivo 11 (Ifakara, Karonga) and manually (uMkhanyakude),
according to thematic areas covered in the topic guides to ensure comparability. Transcription
and broad coding were undertaken by the study coordinators in each country. The lead researcher
in each site kept detailed analytical memos during the coding and analysis process, and regular meet-
ings were held with the researchers in the different sites. All data related to biological markers were
extracted and broadly coded deductively under nodes corresponding to the topic guide, and then the
lead authors further inductively analysed to identify common and refutable thematic areas across the
sites and the different groups and focused on the themes relating to VL and CD4 testing
Ethical approval
Ethical approval was obtained from the Internal Review Boards of the Ifakara Health Institute (14-
2017) and National Institute for Medical Research for Tanzania (#2579), National Health Science
Research Committee for Malawi (#1861), the Biomedical Research Ethics Committee for South
Africa (BREC REF: BE400/14) and from the London School of Hygiene and Tropical Medicine
(#13536-1).
Results
Review of CD4 and viral load testing policies
Since 2017, WHO has recommended VL testing as the preferred approach to diagnose and confirm
treatment failure, with testing to be conducted at six and twelve months after ART initiation and
every twelve months thereafter. The guidelines also state that where VL testing is not routinely
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available, CD4 count and clinical monitoring should be used to diagnose treatment failure (World
Health Organization, 2017). In addition, the guidance recognises that CD4 remains the best predic-
tor for disease status and immediate risk of death, and indicates that all patients entering or re-enter-
ing care should receive a CD4 test at treatment baseline and as clinically indicated for patients who
are unstable or with advanced HIV disease (World Health Organization, 2017).
All three countries revised their national policies on the use of CD4 and VL tests for HIV care and
treatment during the study period (Table 2). In Tanzania, CD4 counts were indicated for determin-
ing eligibility for ART, and every six months thereafter to monitor immunologic response to ART
and aid decision-making for transitioning patients with poor immunological response to second-
line regimens (National AIDS Control Programme, 2015). In the 6th National Guidelines for the
Management of HIV and AIDS, CD4 counts were no longer required to determine ART eligibility
under UTT policies, but were still indicated for detecting opportunistic infections (Ministry of
Health, Community Development, Gender, Elderly and Children & The United Republic of Tanza-
nia, 2017) and broadly align to the WHO guidance. The use of VL testing was adopted in 2015 in
Tanzania for all patients after six months on ART, with CD4 counts to be conducted if VL testing
is not available (Ministry of Health and Social Welfare & National AIDS Control Programme, 2015;
National AIDS Control Programme, 2015).
In Malawi, throughout the study period routine CD4 testing was not required for ART initiation
nor for monitoring patients on ART (The Ministry of Health Malawi, 2013). The policy was refined
in 2016, such that ‘targeted CD4 counts may be requested by specialist clinicians for complicated
cases’ (The Ministry of Health Malawi, 2016). Viral load monitoring was introduced into treatment
guidelines in 2011 to monitor treatment failure, and was first included as part of routine care in 2016,
at 6 months after ART initiation and then every 2 years thereafter (The Ministry of Health &Malawi,
2016).
In contrast, policy in South Africa increasingly included a role for CD4 testing over the study
period. In 2013 and 2015, national policies specified CD4 testing at baseline and annually. In
2017, policy aligned with WHO recommendation to increase the testing frequency to every six
months until a patient achieved viral suppression (National Department of Health. South Africa,
2017). Routine VL testing to assess virological failure was first included in policy in 2015 with sche-
duling aligning to theWHO recommendation (National Department of Health. South Africa., 2015).
Implementation of CD4 and VL testing at the facility level: facility survey findings
General availability of CD4 and VL tests
In uMkhanyakude (South Africa), the availability of facility-based CD4 testing increased from 0% to
82% (14/17) of facilities between rounds 1 and 3, and turnaround times for CD4 test results reduced
slightly from an average of 3 days to 2.6 days (table 4). In Ifakara (Tanzania), average turnaround
times for CD4 tests also improved from 3.66–1 days over the same time period, but the availability
of CD4 testing reduced from 67% (8/12) of facilities in round 1 to 17% (2/12) facilities in round 3. In
Karonga (Malawi), all facilities offered CD4 testing in round 1 (6/6), while no facilities provided CD4
testing by round 3.
Viral load testing was offered by all facilities in all three settings by the third survey round (table
4). In uMkhanyakude, the majority of facilities (88%; 15/17) offered on-site tests, whereas in both
Ifakara and Karonga, the majority of facilities reported that samples for viral load testing were
only available at another facility (83%; 10/12 facilities in Ifakara and 80%, 4/5 of facilities in Kar-
onga). The average turnaround time for VL tests across the facilities was long in both Ifakara
(29.4 days) and Karonga (44.8 days). In uMkhanyakude, the average turnaround was 3.4 days.
Pre-ART initiation tests availability
In uMkhanyakude, in line with national policy, the proportion of facilities requiring a CD4 test to
initiate ART decreased from 100% in round 2 to 53% in round 3. Similarly, practice in Karonga
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and Ifakara aligned with the changing policy and in both settings, the proportion of facilities that
reported requiring a CD4 test for ART initiation declined from 100% (12 facilities) to 8% (1/12 facili-
ties) between round 2 and 3 in Ifakara, and from 60% (4/6 facilities) to 0% between round 2 and 3 in
Karonga.
Post-ART initiation testing
In accordance with national policy, in rounds 1 and 2, the majority of facilities (88% [15/17 facilities]
and 71% [13/18 facilities], respectively) in uMkhanyakude reported conducting annual post-ART
initiation CD4 tests on stable patients, while the information was not available for round 3 (table
5). Also in accordance with national policy in Ifakara, 92% of facilities in round 1 (11/12 facilities),
and 100% in round 2 (12/12 facilities), reported the same tests being conducted every six months,
despite the limited availability already discussed, with no information available in round 3. In Kar-
onga in round 2, despite policy guiding the use of CD4 tests for complicated cases, it was reported
that 60% of facilities [4/6 facilities] were not conducting CD4 tests post ART initiation (nor were they
available in the sites) and this information was not collected in round 3.
In all sites, no data were available for round 1 and 2 on the proportion of facilities with VL use to
monitor treatment failure. However, in round 3, the majority of facilities in all three sites, in accord-
ance with their respective country policies, reported using VL to monitor treatment failure, followed
by clinical symptoms and then CD4 counts in one facility in both uMkhanyakude and Ifakara (table
6). The majority of facilities across all three sites and all three rounds reported conducting pill counts
or asking about pill taking to measure ART adherence. In addition to these two mechanisms, all three
sites also reported VL testing for this purpose in round 3, albeit at different levels of coverage across
Table 4. Availability of CD4 and VL tests by HDSS site and survey round.
Site (Country)
uMkhanyakude Karonga Ifakara
(South Africa) (Malawi) (Tanzania)
Round R1 R2 R3 R1 R2 R3 R1 R2 R3
Number of
facilities
17 18 17 6 6 5 12 12 12
Timing of
survey round
Jan-
15
May-
June
16
Dec
17-
Jan
18
Dec-
13
May-
15
Nov-
Dec
17
Nov 13
– Mar
14
Sept-
Oct
15
Nov-
Dec
17
Availability and
location of CD4
tests
Tests not
offered
0% 0% 0% 0% 0% 100% 0% 0% 0%
At facility 0% 12% 82% 20% 20% 0% 67% 67% 17%
Patient sent
elsewhere
0% 12% 0% 80% 80% 0% 50% 33% 0%
Sample sent
elsewhere
88% 71% 18% 20% 20% 0% 17% 0% 83%
CD4 result turnaround time (average
[range]) (days)
3.06
[1-
7]
2.47 [1-
5]
2.63 [1-
5]
1.2
[1-
2]
1 [0-
2]
No
Data
3.58 [0-
30]
1.16
[0-7]
1 [1-1]
Availability of
viral load
testing
No routine viral
load offered
ND ND 0% ND ND 0% ND ND 0%
Viral load
offered at the
facility
ND ND 88% ND ND 20% ND ND 17%
Viral load
offered at
another
facility
ND ND 12% ND ND 80% ND ND 83%
Viral test result turnaround time
(average[range]) (days)
ND ND 3.4 [2-
5]
ND ND 44.8
[30-
60]
ND ND 29.4
[2-
90]
*Key for colour coding: Red: 0%–25% of facilities implemented, yellow: 26%–79% of facilities implemented; green: 80%–100% of
facilities implemented.
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facilities (uMkanyakude 76%; Ifakara 8%; Karonga 60%). The action taken in the event of low adher-
ence varied substantially by round (table 6). Adherence counselling increased substantially from
being conducted in almost no facilities in round 1 to the majority of facilities in all sites by rounds
2 and 3.
Implementation realities: perspectives of key informants, providers and service users,
Two themes emerged from the analysis of our qualitative data with regards to experiences of using
VL and CD4 tests: (i) implementation challenges and (ii) understanding and perceived values of VL
and CD4 results.
Implementation challenges
Key informants recognised the implementation challenges of conducting both VL and CD4 tests.
One KI in Malawi described VL testing as ‘even more demanding’ than CD4 testing. Long turn-
around times were frequently mentioned, often attributed to the lack of point-of-care testing and
the need to transport samples to facilities with VL machines.
“molecular laboratories are few…maybe there are just 13 molecular laboratories I think,…we have 700 health
facilities providing ART so there’s a big logistical challenge to get all the samples into those laboratories and get the
results back to the patient. It’s hugely demanding, very, very complicated. It’s a real struggle. (KII, Malawi)
In both Ifakara and Karonga, where VL testing took place in centralised testing facilities, delays were
reported.
“The test results take like one or two months, as they are not done here, we take the samples to XXX regional
hospital, and sometimes we face challenges when the sample failed to read them, we are then supposed to take
samples again and wait for one or two months again”. (IDI, Health care worker, Ifakara)
Table 5. Pre-ART initiation tests by HDSS site and survey round.
Site
(Country)
uMkhanyakude Karonga Ifakara
(South Africa) (Malawi) (Tanzania)
Round R1 R2 R3 R1 R2 R3 R1 R2 R3
Number of
facilities
17 18 17 6 6 5 12 12 12
Timing of
survey
round
Jan-
15
May-
June
16
Dec 17-
Jan
18
Dec-
13
May-
15
Nov-
Dec
17
Nov
13–
Mar
14
Sept-
Oct
15
Nov-
Dec
17
CD4 tests required prior to ART
initiation
94% 100% 53% 100% 60% 0% 92% 100% 8%
What determines
ART initiation
Clinical
staging
only
0% 0% 0% 20% 20% 0% 0% 0% 0%
Clinical
staging or
CD4
0% 18% 0% 0% 80% 0% 0% 92% 0%
CD4 only 100% 71% 0% 80% 0% 0% 83% 8% 0%
When is ART
initiated for non-
pregnant patients
Clinical
stage 4
6% 59% 0% 60% 40% 0% 58% 100% 0%
Clinical
stage 3 or
4
53% 65% 0% 100% 80% 0% 50% 100% 0%
CD4 < 250 0% 35% 0% 0% 0% 0% 50% 100% 0%
CD4 < 350 53% 29% 0% 80% 0% 0% 83% 100% 0%
CD4 < 500 65% 100% 0% 0% 80% 0% 0% 8% 0%
All eligible 0% 0% 100% 0% 0% 100% 0% 0% 100%
*Key for colour coding: Red: 0%–25% of facilities implemented, yellow: 26%–79% of facilities implemented; green: 80%–100% of
facilities implemented.
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In practice, systems for the transportation of samples were inefficient due to their high costs which
led to some providers waiting to collect multiple samples to make the transportation more economi-
cal, leading to longer turnaround time. In some facilities, a lack of refrigeration options compounded
the logistical challenges and also contributed to these higher costs:
“I will take the blood to xxx to be kept into the refrigerator… That is also a challenge as you have seen the distance
from here to xxx. I have to hire a motor cycle to there. I have to convince them to get 5–10 within a day instead of
taking the sample of 1 or two patients… It cost… . Yes. It means I have to assess them on Wednesday those who
have reached 6 months qualify for the test. If I get only 3, I will request them to come the next Wednesday know-
ingly that if I have these 3, the next Wednesday I will not miss other 3 or 4. And, I will pick together and send to
xxx” (IDI, Health care worker, Ifakara)
Table 6. Post ART CD4 testing and adherence monitoring by HDSS site and survey round.
Site (Country)
uMkhanyakude Karonga Ifakara
(South Africa) (Malawi) (Tanzania)
Round R1 R2 R3 R1 R2 R3 R1 R2 R3
Number of facilities 17 18 17 6 6 5 12 12 12
Timing of survey round Jan-
15
May-
June
16
Dec
17-
Jan
18
Dec-
13
May-
15
Nov-
Dec
17
Nov 13
– Mar
14
Sept-
Oct
15
Nov-
Dec
17
Frequency of CD4
tests on stable
ART patients
None 0% 0% ND 40% 60% ND 0% 0% ND
When sick 0% 0% ND 0% 0% ND 0% 0% ND
Every 3 months 0% 12% ND 0% 0% ND 0% 0% ND
Every 6 months 12% 18% ND 40% 0% ND 92% 100% ND
Annually 88% 71% ND 0% 0% ND 0% 0% ND
Monitoring
treatment failure
CD4 counts ND ND 18% ND ND 0% ND ND 25%
viral loads ND ND 71% ND ND 100% ND ND 100%
clinical
symptoms
ND ND 24% ND ND 80% ND ND 100%
Adherence
monitoring post
ART initiation
None 0% 0% 6% 0% 0% 0% 0% 0% 0%
Pill counts 35% 12% 18% 100% 100% 100% 58% 33% 100%
Ask about pill
taking
94% 88% 65% 40% 100% 100% 83% 100% 33%
Viral loads ND ND 76% ND ND 60% ND ND 8%
CD4 counts ND ND 0% ND ND 0% ND ND 0%
Asked two weeks
after initiation
0% 6% 0% 0% 0% 0% 0% 0% 0%
file checking 0% 6% 0% 0% 0% 0% 0% 0% 0%
by visit date 0% 0% 0% 0% 0% 20% 8% 0% 8%
Action if low
adherence for
ART patients
None 0% 0% 0% 0% 0% 20% 0% 0% 0%
Stop ART 0% 0% 6% 0% 0% 20% 17% 0% 0%
Provide a pill box 18% 6% 12% 0% 0% 0% 42% 0% 0%
support groups 29% 53% 6% 20% 0% 40% 0% 33% 0%
psycho-social
counselling
71% 94% 53% 100% 20% 80% 100% 17% 0%
home visit 0% 29% 0% 0% 20% 20% 0% 0% 17%
home-based care 24% 47% 12% 0% 0% 0% 17% 0% 33%
directly observed
therapy
12% 18% 0% 0% 0% 40% 8% 0% 0%
adherence
counselling
12% 94% 71% 0% 100% 100% 8% 83% 100%
reduce refill
period
0% 41% 47% 0% 40% 100% 0% 8% 25%
Refer client to
higher level
facility
0% 0% 0% 0% 0% 0% 0% 8% 0%
Insist on bringing
a treatment
partner
0% 0% 0% 0% 0% 20% 8% 0% 0%
*Key for colour coding: Red: 0%–25% of facilities implemented, yellow: 26%–79% of facilities implemented; green: 80%–100% of
facilities implemented.
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Nevertheless, health workers from some facilities reported gradual improvements in terms of the
regularity of returning results:
“there has been some improvement on transportation. We now have riders who bring us those results on Tuesdays
and Thursdays”. (IDI, Health care worker, Ifakara)
Some KIs mentioned inadequate training for staff and machine breakdowns as factors which perpe-
tuated slow implementation of routine VL testing:
“It’s not happening most of the time because we don’t have enough capacity…Or the machine is not working
well, so there is that breakdown. Sometimes we have the machine, it is working, but our staff do not have the
required skills… so that’s the challenge.” (KII, Tanzania)
Some healthcare workers noted similar challenges with CD4 counts, but felt that this was a lesser
concern because these tests were no longer needed for assessing eligibility for treatment:
“…we stopped testing for CD4 a long time ago, because our machine is not working and these days it doesn’t even
matter because it is no longer a criterion for using or not using ARVs”. (IDI, health care worker, Karonga)
In two facilities, health workers felt that procedures for CD4 testing were not always followed, due to
a lack of availability of the new guidelines, training in their application, or as a result of being over-
worked and having insufficient time.
“Previously we were waiting for six months after putting her on medication… now there is something new…
though I have asked for the guidelines but we are yet to receive them” (IDI health care worker, Ifakara)
“You may find those whom I deputise are not acting properly. They may not have tested CD4 for some patients for
a long period…maybe due to overwork or they don’t have sufficient experience… ” (IDI health care worker,
Ifakara)
In some cases, where health workers were impeded from systematically implementing the guide-
lines due to logistical challenges, they developed their own strategies to prioritise the patients that
they felt were at greatest need of the tests:
“As part of patient monitoring, each patient on treatment has their VL tested after each six months to see how
they are faring and to aid the early detection of any problems. In principle we were supposed to call the lab per-
sonnel… but as you have seen our rooms are small and there is no space for that so we made arrangements that
when our clients reach the lab, they are given first priority not to stay in queue” (IDI, Health care worker, Ifakara)
In other cases, prioritisation by the health workers was made in terms of spending time on explaining
the test results, so that some patients felt unaware of their meaning:
“You find that after taking the blood tests when the results come back. They no longer have enough time to sit
down with you… the results came back but they did not explain anything to me.… You don’t get to know
about it. You just keep on taking the treatment. They only give you attention if it’s your first time taking the treat-
ment. When you have become the regular they no longer care”.(Woman initiated on ART under Option B+,
South Africa.)
Understanding and perceived values of VL and CD4 results
In all countries, KIs were well versed on the role of VL testing to monitor treatment adherence. In
some instances, the KIs suggested that VL testing had superseded CD4 counts, with some mention-
ing the redundancy of CD4 testing to assess ART eligibility and its inability to assess non-adherence
and the emergence of resistance.
“We now emphasize viral load, that’s why we are now using more viral load machines than the CD4, because with
the viral load, tests we can capture the viral count…maybe there is some resistance… in this case a CD4 count
will not be as helpful as a viral load test.” (KII, Malawi)
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One only participant, in Malawi, articulated the additional role of CD4 over and beyond VL testing,
suggesting that there was now a ‘re-appreciation of CD4 count as a tool for risk stratification and to
identify patients who are high risk and need extra care’ (KII, Malawi)
Healthcare workers in all settings recognised the value of both CD4 and VL tests to guide the
clinical care of their patients. Some health workers appreciated the added value of VL tests over
CD4 for determining when to change regimens, however this benefit was somewhat offset by the
common delays that were experienced in receiving results back:
“Now things have been improved. Previously the decision to change from first to second line was based on CD4
count and clinical test. But now viral load helps us to know the patient’s status… so it is easier to change to second
line although it takes time to wait for results” (health care worker, Ifakara).
However, in each setting, many women living with HIV had no or limited understanding about
the meaning or utility of CD4 and VL tests, with some reporting having never heard about
them:
I. Has it ever happened that you were taken blood sample to measure your viral load?
R: No, its only today that we have been taken blood sample but we don’t know the purpose of blood sample taken.
They only said we are taking blood sample to check if drugs are working properly but if we find that drugs have
side effects we change and give another type of drugs. (IDI, Woman living with HIV from routine care and treat-
ment, Malawi)
“I have had about CD4 count but I don’t think I can actually explain what it is”. (IDI, Woman living with HIV
initiated under Option B+ during this pregnancy, Malawi)
In Ifakara, all of the women who started ART during their current pregnancy (under Option B+)
stated they had never had a CD4 or VL test conducted that they were aware of, although some
had heard about CD4 tests from the media and were keen to be tested but did not have the
means nor resources to make this happen.
“CD4, I heard it from the media. And, there is a day we came here and we were asked if we have tested for CD4. I
said no. They said, I must test. But, they didn’t give me the means to go to test or test me”. (IDI, Woman living
with HIV initiated under Option B+ during this pregnancy, Ifakara, Tanzania)
For some women who had received their results, the experience was memorable.
I: Have you ever had a CD4 count
R: Yes I have had one but that was a long time ago
I:How was it then?
R:I think it was fine because it was about 400 if I remember well. (IDI, Woman living with HIV currently not
engaged in care, Karonga, Malawi)
Despite the service user reports of limited implementation some participants in all countries
expressed a desire for these measures (primarily CD4 counts) to know more about their health.
“I would like to know about CD4, when they increase and decrease, and to know my health progress generally”.
(IDI, Woman living with HIV from routine care and treatment, Ifakara, Tanzania)
They help your immune system. To help you when your immune system is very low. When your CD4 count is high
then it means you are protected.… Yes, I have measured my CD4 count, I am not sure if I was still protected
because they were low… They were low because they were even less than 600. (IDI, Woman living with HIV
initiated on ART under Option B+ during this pregnancy, South Africa)
Some KIs raised concerns over how test results were being interpreted and relayed to clients.
KIs described that even when providers understood the meaning of virally suppressed results,
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they sometimes chose to hide the interpretation from patients, believing that it may prompt sexual
risk-taking:
“if you are consistent on ARVs and your viral load is at zero, even if you have sex without being protected, you
cannot transmit the virus. But we are trying not to relay this message as people may misinterpret it thinking that
“now I cannot transmit”. The way we are doing with male circumcision, some are understanding that when I am
circumcised it means I will not catch any virus” (KII, Malawi)
“That is an issue: the viral load are not in all facilities. They are so few and patients are not aware when it comes
to viral load checking or testing. It is something that it will take a bit of time for people to grasp”. (KII, Tanzania)
Such insinuations were also present amongst healthcare workers. Not all healthcare workers were
fully confident in explaining the purpose or the national policies regarding the scheduling of each
test, particularly for VL testing. In all sites, some health care workers reported valuing VL tests
because they enabled them to assess adherence, or in some cases to check if patients were ‘doing
as they are told’. In Karonga and Ifakara, VL testing was reportedly used first and foremost to moni-
tor adherence failure, with very few references made to treatment failure, suggesting a focus on the
failings of the women’s treatment taking before questioning the drug effectiveness.
“I’m not sure if I am correct in this… from my knowledge, it is that after you test the mother with viral load and the
virus are not detected, it means she takes her medications as it’s indicated and she follows the advice that we give her
… and if the virus are detected it means that the mother is irresponsible and doesn’t follow our guidance so the viral
… load is detectable… so we counsel them on taking their medications…”. (IDI, Health care worker, Karonga)
Some service users also felt that the main purpose of the tests was to enable the health workers to
‘check’ on them.
“… I personally think that it [testing] is because they want to see if you are taking your treatment correctly and to
check if there are any changes”. (IDI,Woman initiated ART under Option B+ during this pregnancy, South Africa)
Discussion
We investigated the extent to which WHO guidelines on CD4 and VL testing have been adopted in
national policy, and implemented in health facilities in rural Tanzania, Malawi and South Africa. We
also explored challenges to the implementation of these tests from the perspectives of stakeholders, pro-
viders and patients. In all three study countries, national policies on the use of CD4 and VL tests for HIV
care and treatment were revised during the study period. In line with WHO guidance, VL testing
became universally available in all three settings over the study period (World Health Organization,
2017), although significant challenges remain with, for example, long turnaround times to get results.
The picture for CD4 was more mixed. In Tanzania, CD4 counts were no longer required to deter-
mine ART eligibility, but were still recommended to detect opportunistic infections, in Malawi CD4
counts may be requested in ‘complex cases’, and in South Africa their role appeared to have increased
over time. The availability of CD4 tests showed facility based CD4 testing increased, and turnaround
times reduced, over time in South Africa. However, the picture in both Tanzania and Malawi was less
positive. Whereas turnaround times for CD4 tests improved in Tanzania, facility-based testing over-
all greatly reduced. In the surveyed facilities in Malawi, CD4 test coverage went from 100% to zero
over the study period. This is of concern given that WHO recommend countries retain their capacity
to conduct CD4 testing at diagnosis and up to ART initiation, and CD4 counts remain useful in guid-
ing the clinical management of people failing treatment or re-engaging in care (Rice et al., 2019).
Some key informants suggested the promotion of VL testing had, to some degree, diminished the
role of CD4 in monitoring and informing clinical decisions. Recent publications have suggested
that donor support for CD4 testing has decreased in recent years and that, contrary to WHO guide-
lines, not only post but also pre-treatment CD4 monitoring has reduced in a number of resource-
limited countries, (Medecins sans Frontières, 2017; Nash & Robertson, 2019; Rice et al., 2019).
Related to this, a number of health workers reported that their concern over issues such as a lack
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of CD4 reagents had lessened (despite CD4 testing still being required for the clinical management of
cases). Our finding supports the recent expression of anxiety that guidelines promoting Universal
test and treat may be being misinterpreted (Ehrenkranz et al., 2019). Specifically, that the importance
of CD4 monitoring in identifying and treating people at risk of advanced disease has been erro-
neously dismissed due to the attention given to scaling up VL testing.
Our study found sub-optimal implementation of tests, insomuch as inadequate scheduling, long
turnaround times (mainly in relation to VL), and procedures not being followed (mainly in relation
to CD4) compromised the utility of the markers. Challenges leading to sub-optimal implementation
in these settings included lack of facility space, a lack of refrigeration, and suboptimal laboratory
capacity. Developments in the use of point of care testing are positive with evidence to suggest
such testing is feasible, acceptable and can increase coverage and effectively identify treatment fail-
ures (for viral load testing) (Nicholas et al., 2019; Pham et al., 2016). Our study supports their rec-
ommendations of the need for continued efforts to train staff regularly, monitor the programme and
promote demand for the tests.
Additionally, our study highlighted various challenges in health worker capacity to communicate the
meaning of test results to patients and populations. In all three countries women living with HIV
reported knowing nothing or little about either tests and, in some settings, having not received such
a test. Other studies have reported similar findings. Potentially as a result of a misinterpretation of
the guidelines, CD4 testing has been reported as being no longer recommended (unless VL testing is
unavailable) in Cameroon, Kenya, Malawi, Namibia, Swaziland, Thailand and Uganda (United States
Agency Intenational Development, 2016). Sub-optimal implementation of VL testing has been reported
in Kenya, with only one third of individuals with unsuppressed VL receiving a confirmatory / repeat test
as required by national guidelines (Ehrenkranz et al., 2019). In Lesotho, one study found only one quar-
ter of patients with a first unsuppressed VL to be managed correctly according to WHO guidelines fol-
lowing the roll-out of routine VL monitoring (Glass et al., 2019). In addition to the benefits of frontline
access, these biomarkers also hold utility for patients by representing a tangible number through which
they can measure and understand their health status (Horter et al., 2019; Renju et al., 2017).
Our study has various strengths and limitations that need to be considered when interpreting our
data. Firstly, the number and composition of the participants included in the key informant interviews
in South Africa differed from the other two countries. In South Africa the five key informants were all
from the provincial level and their expertise focused primarily on the policy formulation and adoption,
as opposed to the implementation at the facility level. Secondly the surveyed health facilities were
included as they served the health and demographic surveillance site populations, and were not nation-
ally representative. However, these facilities did represent those found in rural areas in each country, we
recommend that further health systems research of this nature be conducted in more sites within each
country to further explore the wider generalisability of our findings. Thirdly the small number of facili-
ties prohibited any statistical analysis of trends. The survey findings are purely descriptive and we allo-
cated arbitrary cut-offs to illustrate low, medium and high levels of implementation across the different
facilities. Fourthly the health facility managers at the time of the survey, provided the responses, these
may be subject to reporting biases and could lead to skewed estimates of the services available. Fifthly,
various changes were made to the facility survey between rounds, meaning some variables were not col-
lected in all three rounds, preventing the longitudinal analysis in these instances. Lastly with regards to
the qualitative data, social desirability bias may underlie some of the responses, leading them to over-
emphasise positive or negative experiences. However, all the interviewers were experienced in building a
rapport with their participants and provided a full explanation of the study and rationale in order to
mitigate this potential bias. The main strength of this analysis is its provision of a detailed multi-faceted
case study looking at the adoption and implementation of different biological marker tests from the per-
spective of the policy makers, providers and service users at a five year period when international gui-
dance on HIV care and treatment was rapidly changing.
Over the past year or two there have been calls for vigilance and oversight to ensure we retain our
capacity to conduct CD4 testing at diagnosis and up to ART initiation whilst scaling up VL testing
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(Nash & Robertson, 2019; Rice et al., 2019), and for CD4 and VL test results to remain widely avail-
able to frontline providers to inform clinical management (Ehrenkranz et al., 2019). In highlighting a
perception that the role of CD4 testing has diminished, that the implementation of both CD4 and VL
testing is sub-optimal, and challenges in communicating and understanding the utility of these bio-
markers, our results support calls for vigilance and oversight. Our findings suggest that more
research is needed to explore why current guidance are not adequate to ensure a clear and consistent
understanding on the role of the tests at all levels, including at the national level. This guidance
should also offer direction as to how to relay this message to sub-national levels.
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